KEEPS: The Kronos Early Estrogen Prevention Study

References

• Bergkvist L, Adami H-0, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen—progestin replacement. N Engl J Med 1989;32:293–7
   Google Scholar
• Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen—progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;283:485–91
   PubMed Web of Science ®Google Scholar
• Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. J Am Med Assoc 1997;277:1140–7
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovas-cular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756–62
   Google Scholar
• Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37
   PubMed Web of Science ®Google Scholar
• Bush TL. Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur Heart J 1996;17(Suppl D):9–14
   Google Scholar
• Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Community Health 1989;43:173–8
   Google Scholar
• Hemminki E, McPherson K. Impact of post-menopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. Br Med J 1997;315:149–53
   PubMed Web of Science ®Google Scholar
• Bush TL, Cowan LD, Barrett-Connor E, et al. Estrogen use and all-cause mortality. Prelimin-ary results from the Lipid Research Clinics Program Follow-Up Study. J Am Med Assoc 1983;249:903–6
   Google Scholar
• Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replace-ment therapy. Arch Intern Med 1991;151:75–8
   PubMed Web of Science ®Google Scholar
• Ettinger B, Friedman GD, Bush T, Quesenberry CPJ. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996;87:6–12
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortal-ity. N Engl J Med 1997;336:1769–75
   PubMed Web of Science ®Google Scholar
• Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular dis-ease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991;164:489–94
   Google Scholar
• Humphrey LL, Chan BK, Sox HC. Postmeno-pausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273–84
   Google Scholar
• Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105–10
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998;280:605–13
   Web of Science ®Google Scholar
• Byington RP, Furberg CD, Herrington DM, et al. Effect of estrogen plus progestin on progressionofcarotidatherosclerosisinpostmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol 2002;22:1692–7
   PubMed Web of Science ®Google Scholar
• Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522–9
   PubMed Web of Science ®Google Scholar
• Naftolin F, Taylor HS, Karas R, et al. The Women's Health Initiative (WHI) could not have detected cardioprotective effects of starting hormone therapy during the menopausal transi-tion. Fertil Steril 2004;81:1498–501
   PubMed Web of Science ®Google Scholar
• De Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradio1-17 beta in post-menopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986;62:536–41
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postme-nopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17: 3071–8
   PubMed Web of Science ®Google Scholar
• Alkjaersig N, Fletcher AP, de Ziegler D, Steingold KA, Meldrum DR, Judd HL. Blood coagulation in postmenopausal women given estrogen treatment: comparison of transdermal and oral administration. J Lab Clin Med 1988;111:224–8
   PubMedGoogle Scholar
• Cushman M, Kuller LH, Prentice R, et al. for the Women's Health Initiative Investigators. Estro-gen plus progestin and risk of venous thrombosis. J Am Med Assoc 2004;292:1573–80
   Google Scholar
• Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. J Am Med Assoc 2002;288:980–7
   PubMed Web of Science ®Google Scholar
• Manning PJ, Sutherland WH, Allum AR, de Jong SA, Jones SD. Effect of hormone replace-ment therapy on inflammation-sensitive proteins in post-menopausal women with Type 2 dia-betes. Diabet Med 2002;19: 847–52
   Google Scholar
• Zegura B, Keber I, Sebestjen M, Koenig W. Double blind, randomized study of estradiol replacement therapy on markers of inflammation,coagulationandfibrinolysis.Atherosclerosis 2003;168:123–9
   PubMed Web of Science ®Google Scholar
• Wingrove CS, Garr E, Godsland IF, Stevenson JC. 17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1998;1406:169–74
   PubMed Web of Science ®Google Scholar
• Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36:1797–802
   PubMed Web of Science ®Google Scholar
• Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999;100:96–102
   PubMed Web of Science ®Google Scholar
• Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP. C-reactive protein and myocardial infarction. J Clin Epidemiol 2002;55:445–51
   PubMed Web of Science ®Google Scholar
• Ikeda U, Shimada K. Matrix metalloproteinases and coronary artery diseases. Clin Cardiol 2003;26:55–9
   PubMed Web of Science ®Google Scholar
• Loftus IM, Naylor AR, Goodall S, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 2000;31:40–7
   Google Scholar
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal re-sults from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery athero-sclerosis. A rterioscler Thromb Vasc Biol 1997;17:217–21
   Google Scholar
• Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery athero-sclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998;83:721–6
   Google Scholar
• Williams JK, Anthony MS, Honore EK, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 1995;15:827–36
   PubMed Web of Science ®Google Scholar
• Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestro-gens. J Clin Endocrinol Metab 2001;86:41–7
   Google Scholar
• Manson JE, Hsia J, Johnson K, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. for the Women's Health Initiative Steering Commit-tee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized con-trolled trial. J Am Med Assoc 2004;291:1701–12
   Google Scholar
• Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986;314:1615–20
   PubMed Web of Science ®Google Scholar
• de Lignieres B. Oral micronized progesterone. Clin Tiler 1999;21:41-60; discussion 1–2
   Google Scholar
• Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A rando-mized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939–53
   PubMed Web of Science ®Google Scholar
• Raggi P, Callister TQ, Cooil B, et al. Identifica-tion of patients at increased risk of first unheralded acute myocardial infarction by elec-tron-beam computed tomography. Circulation 2000;101:850–5
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Thal L, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. J Am Med Assoc 2003;289:2651–62
   PubMed Web of Science ®Google Scholar
• Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. J Am Med Assoc 2003;289:2663–72
   PubMed Web of Science ®Google Scholar